ArticleNanomedicine : nanotechnology, biology, and medicine2016
Ferumoxytol nanoparticle uptake in brain during acute neuroinflammation is cell-specific.
Article in Nanomedicine : nanotechnology, biology, and medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 47 citations in OpenAlex.
- USPIO enhanced MR imaging in CNS tumors (UMIC): a study protocol.Nanomedicine (London, England) · 2026Article
- Article
- Iron-oxide nanoparticles selectively enhance the toxicity of pharmacological ascorbate through hydrogen peroxide-dependent DNA damage in non-small cell lung cancer (NSCLC).Free radical biology & medicine · 2025Article
- Ferumoxytol-enhanced MRI assessment of venous Thrombus resolution and macrophage content in a murine deep vein thrombosis model.Thrombosis research · 2024Article
- MRI Detection and Therapeutic Enhancement of Ferumoxytol Internalization in Glioblastoma Cells.Nanomaterials (Basel, Switzerland) · 2024Article
- Pretherapy Ferumoxytol-enhanced MRI to Predict Response to Liposomal Irinotecan in Metastatic Breast Cancer.Radiology. Imaging cancer · 2023Article
- T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticles.Nature communications · 2023Article
- Advances in the application of neuroinflammatory molecular imaging in brain malignancies.Frontiers in immunology · 2023Review
- Undesired impact of iron supplement on MRI assessment of post-treatment glioblastoma.CNS oncology · 2022Article
- A nanoparticle probe for the imaging of autophagic flux in live mice via magnetic resonance and near-infrared fluorescence.Nature biomedical engineering · 2022Article
- Article
- MRI and PET of Brain Tumor Neuroinflammation in the Era of Immunotherapy, From theAJR. American journal of roentgenology · 2022Review
- Advanced MRI Protocols to Discriminate Glioma From Treatment Effects: State of the Art and Future Directions.Frontiers in radiology · 2022Review
- Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle.Theranostics · 2022Review
- Primary central nervous system lymphoma: advances in MRI and PET imaging.Annals of lymphoma · 2021Article
- Tumor recurrence or treatment-related changes following chemoradiation in patients with glioblastoma: does pathology predict outcomes?Journal of neuro-oncology · 2021Article
- Nanoparticles as immunomodulators and translational agents in brain tumors.Journal of neuro-oncology · 2021Review
- Distinguishing Extravascular from Intravascular Ferumoxytol Pools within the Brain: Proof of Concept in Patients with Treated Glioblastoma.AJNR. American journal of neuroradiology · 2020Article
- New Technologies to Image Tumors.Cancer treatment and research · 2020Article
- Brain iron deposition after Ferumoxytol-enhanced MRI: A study of Porcine Brains.Nanotheranostics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Ferumoxytol ultrasmall superparamagnetic iron oxide nanoparticles can enhance contrast between neuroinflamed and normal-appearing brain tissue when used as a contrast agent for high-sensitivity magnetic resonance imaging (MRI). Here we used an anti-dextran antibody (Dx1) that binds the nanoparticle's carboxymethyldextran coating to differentiate ferumoxytol from endogenous iron and localize it unequivocally in brain tissue. Intravenous injection of ferumoxytol into immune-competent rats that harbored human tumor xenograft-induced inflammatory brain lesions resulted in heterogeneous and lesion-specific signal enhancement on MRI scans in vivo. We used Dx1 immunolocalization and electron microscopy to identify ferumoxytol in affected tissue post-MRI. We found that ferumoxytol nanoparticles were taken up by astrocyte endfeet surrounding cerebral vessels, astrocyte processes, and CD163(+)/CD68(+) macrophages, but not by tumor cells. These results provide a biological basis for the delayed imaging changes seen with ferumoxytol and indicate that ferumoxytol-MRI can be used to assess the inflammatory component of brain lesions in the clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.